Regulator encourages schemes to cover the screening, diagnosis, treatment and care of COVID-19 patients

Drickus Maartens • April 17, 2020
Medical schemes regulator, the Council of Medical Schemes (CMS), is encouraging medical schemes to cover the screening, diagnosis, treatment and care for coronavirus (COVID-19) and to consider giving members a premium holiday for three months where certain conditions are met.

In a circular sent to schemes, CMS Chief Executive and Registrar, Dr Sipho Kabane urged medical schemes to ensure that there was continued compliance with their managed care protocols to mitigate the possible negative impact of COVID-19.

At the onset of the pandemic, medical schemes were not obliged to pay for COVID-19 tests where members had tested and received a negative result. Most schemes only paid for tests and relevant treatment when members had tested COVID-19 positive.

Given the seriousness of the pandemic, Dr Kabane said: “The CMS lodged a draft amendment to the Prescribed Minimum Benefit (PMB) regulations with the Minister of Health to cover the screening, diagnosis, treatment and care of COVID-19 as part of the PMB package. The signing and promulgation of coronavirus in the National Gazette and the publication thereof are being handled by the National Department of Health.”

PMBs are a set of defined healthcare benefits to ensure that all medical scheme members have access to certain minimum health services, regardless of the benefit option they have selected. They are aimed at protecting medical scheme members from catastrophic financial liabilities in the event of a health crisis.

The CMS said that to ensure member protection through continued access to quality healthcare, the regulator encourages medical schemes to assist vulnerable members who cannot pay contributions due to loss of income as a result of the coronavirus pandemic and subsequent lockdown. “Schemes should investigate all disruptions to member contributions on a case by case basis and determine the merits thereof, before suspension or termination of membership,” continued Dr Kabane.

The CMS said that where a member had accumulated sufficient savings in their Personal Medical Savings Account (PMSA) for a specific period, it would be in the public interest, to grant medical schemes exemptions from complying with their registered rules to use their savings to offset member contributions.

The regulator said Small, Medium and Micro-Sized Enterprises (SMMEs), seeking financial relief from medical schemes to protect their employees’ membership cover should make a case to their respective medical scheme, demonstrating the financial impact caused by the lockdown due to the COVID-19 pandemic. The CMS said consideration must be given to SMME’s ability to financially recover and to repay the medical scheme post the lockdown period.

“To ensure that medical scheme members have continued access to healthcare services and to prevent the possible exploitation of patients as a result of the COVID-19 pandemic, the CMS is facilitating an Industry-wide engagement to develop a price and tariff negotiations framework,” said Dr Kabane

“In this initiative, the CMS is working with industry associations such as the Board of Healthcare Funders (BHF) and Health Funders Association (HFA), with the support of the National Department of Health. CMS’ role is to ensure that negotiations will benefit all medical scheme members,” he said.

Finally, Dr Kabane indicated that as per Circular 23 of 2020, CMS is accepting exemption applications for the postponement of Annual General Elections (AGM)and Trustee elections. “We note that during this period, schemes might not be unable to host their respective annual AGMs so they should apply for exemptions for postponement no later than 30 April 2020, he said.
Dr Mpho Ramabulana stresses the importance of early detection of colorectal cancer.
April 11, 2025
Colorectal cancer, one of the most prevalent yet preventable cancers, can develop in the colon or rectum, often starting as small polyps that can quietly become malignant if left unchecked. Dr Mpho Ramabulana, a colorectal surgeon and gastroenterologist at Netcare Akasia Hospital, underscores the life-saving power of vigilance and the importance of early detection.
Cardiologist Dr Robert Routier and cardiothoracic intensive care unit manager Sr Nondumiso Fakude
April 1, 2025
Cardiologist Dr Robert Routier urges the public to check their personal risk factors regularly to help prevent or manage cardiovascular disease.
Obstetrician and gynaecologist Dr Natalie Odell
March 26, 2025
The physical strain pregnancy puts on an expectant mother’s body should not be underestimated. An obstetrician gynaecologist offers her insights for alleviating discomfort and promoting wellbeing with exercise and stretching throughout pregnancy.
Dr Patience Sigwadi
March 19, 2025
Dr Patience Sigwadi, a leading paediatric nephrologist practising at Netcare Unitas Hospital in Centurion, has issued an urgent call for increased focus on skills development to address the escalating kidney disease crisis among children in South Africa.
Paediatric Nephrologist Prof Rajendra Bhimma
March 11, 2025
Paediatric Nephrologist Professor Bhimma was recently awarded the Fellowship to acknowledge his extensive work in research, community-based outreach and teaching of paediatric nephrology, among others.
Prof Bhekifa Dube
March 7, 2025
Netcare congratulates Professor Bhekifa Dube on his invitation to join the European Society for Vascular Surgery's clinical practice guidelines committee. His selection as the only specialist from the continent highlights the significance of this achievement on the global stage.
Rare Disease Day on 28 February 2025
February 28, 2025
The lives of millions of South Africans with a litany of rare diseases can be vastly improved, and even saved, by addressing challenges in identifying, studying and treating their conditions. With Rare Disease Day on the 28th of February 2025, the Rare Diseases Access Initiative (RDAI) is driving an evolution of the country’s healthcare, through innovative strategies to better care for over 4.2million people living with an estimated 7000 rare diseases. “As our healthcare system faces significant changes in the years ahead, it is vital that we also advocate for people living with rare diseases in South Africa, especially those with limited healthcare access,” said Kelly du Plessis, CEO of Rare Diseases South Africa (RDSA), a member of RDAI. “As part of our ongoing research and awareness efforts, RDAI has conducted an initial analysis of the incidence and prevalence of rare diseases within the country.” This research will assist in improving access to healthcare, policy development, and patient advocacy, while giving critical insight into the challenges faced by patients. “According to research, some rare diseases affect fewer than 1 in a million people, while others, such as Down syndrome, cystic fibrosis, and haemophilia, have a more recognisable prevalence,” says Dr. Helen Malherbe, RDAI lead researcher on rare disease prevalence data. “Many conditions are undetected, underdiagnosed or misdiagnosed, with too many having no information available about them at all.” The RDAI was formed in 2019 to promote a more favourable environment for those impacted by rare diseases in South Africa. Participants include Ampath, the Board of Healthcare Funders (BHF), Discovery Health, Genetic Counsellors South Africa (SASHG), the Government Employees Medical Scheme (GEMS), Health Funders Association (HFA), Medihelp, Medscheme, North-West University (NWU), Rare Diseases South Africa (RDSA), the South African Medical Association (SAMA) and The South African Medical Technology Industry Association (SAMED). The Council for Medical Schemes (CMS) participates as an observer. In the same year, Rare Disease International signed a memorandum of understanding with the World Health Organisation leading to an international rare disease policy framework. In 2021, the United Nations General Assembly moved to adopt a resolution recognising 300 million people living with rare diseases worldwide. “A general lack of awareness and delayed diagnosis remain major hurdles for those affected by rare diseases. Policymakers and healthcare stakeholders need to prioritise access to treatment, diagnosis, and support for rare disease patients,” says Bada Pharasi, CEO of IPASA, “Through this initiative, working collaboratively with stakeholders at every level of the healthcare supply chain, we can bring real and meaningful change to those affected, including family members and care givers, through smart and efficient strategies.” The globally agreed definition of a rare disease is any medical condition with a specific pattern of clinical signs, symptoms, and findings that affects fewer than or equal to 1 in 2000 persons in a population. “Most are genetic, and some are inherited and passed down in families,” Malherbe says. “Some affect only the patient’s genetic recipe, while others may be acquired during life due to infection, trauma, or environmental effects. For many, the cause is still unknown. “These conditions mainly affect children, as they are largely incurable and many are life-threatening. Some require specialised and co-ordinated care, some have limited and expensive treatment options, while others have no information or effective treatments at all,” she adds. The RDAI is calling for a patient-centred care model built on equitable access, transparency and efficiency. Naturally, this model calls for the open participation of patients, the healthcare industry, health professionals, and the Government. “The most critical elements are robust diagnosis standards, improved access to treatment, data collection and management, co-ordination of care, measurement of outcomes and ongoing collaborative research,” du Plessis says. “We need to establish rare disease advisory committees, map gaps and opportunities, establish system requirements, create a roadmap and plan a phased implementation with clear timelines.” The RDAI states that these policy development steps would be a start in quantifying the disease burden and defining standards of care. This would be followed by building and strengthening the capacity to facilitate appropriate diagnosis, treatment, continuity and data monitoring. Thoneshan Naidoo, Chief Executive Officer of the Health Funders Association noted that, “We appreciate the unique opportunity provided by RDAI which enables stakeholders across the industry to work together and identify strategies that improve equitable access to the appropriate diagnosis, treatment and healthcare services for rare disease patients, in an affordable and sustainable manner, taking account of the other pressing needs across the healthcare system.” “True innovation in healthcare is only possible through partnerships and joint advocacy efforts that raise awareness and improve access to treatment. Our long-term goal is the development of a rare diseases policy framework and guidelines for coordinated care,” says Pharasi. “Our members are united in the commitment to unlocking improved patient outcomes and improving access to services and robust health needs assessment facilities.” he concludes. About RDAI The Rare Diseases Access Initiative (RDAI) is dedicated to advocating for improved healthcare access, policy development, and patient support for those affected by rare diseases in South Africa. The initiative brings together key healthcare stakeholders, including pharmaceutical associations, funders, genetic specialists, and patient advocacy groups, to drive impactful change. About RDSA Founded in 2013, Rare Diseases South Africa (RDSA) is a non-profit organisation advocating to ensure that people living with rare diseases and congenital disorders experience greater recognition, support, improved health service and better overall quality of life. Started out of personal need following the diagnosis of organisation founder, Kelly du Plessis' son, it became evident that there was a lack of awareness and support for rare diseases in general in South Africa. About IPASA The Innovative Pharmaceutical Association South Africa (IPASA) is a voluntary trade association representing 24 leading pharmaceutical companies committed to research, development, and innovation. Our mission is to drive healthcare advancement by advocating for policies that improve patient access to safe, high-quality, and affordable medicines.
Gastroenterologist Dr Barbara Makumbi explains the toll acid reflux can take on your health
February 26, 2025
Gastroenterologist Dr. Barbara Makumbi discusses common risk factors and offers tips for managing reflux and the longer-term condition known as gastroesophageal reflux disease (GORD).
Netcare St Anne’s Hospital emergency department now has both trauma and emergency  specialists.
February 19, 2025
From treating trauma injuries caused by wildlife, road accidents and sports, to heart attacks, stroke, or the sudden onset of other concerning medical symptoms – the emergency department at Netcare St Anne’s Hospital never sleeps.
Making sense of self-harm
February 10, 2025
As many as one in ten teenagers may self-harm, often in secret, concealing the scars or evidence of their injuries. As Teen Suicide Prevention Week approaches, Netcare Akeso is highlighting the often-hidden struggle of self-harm among young people.
More Posts
Share by: